ERBB2 and breast cancer: In patients with early-stage breast cancer, pCR after NAC is associated with favorable long-term outcomes [3], and particularly in HER2-positive breast cancer, pCR is strongly prognostic for event-free survival (EFS) and overall survival (OS) [4].